News

Explore by Category
News

KidneyIntelXTM Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time

June 28, 2021

Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and pharma collaborations NEW YORK, June 28, 2021 – Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic…

News

Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment

June 07, 2021
News

Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care

June 03, 2021
News

Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health

May 20, 2021
News

U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing

April 22, 2021
News

KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)

April 20, 2021
News

Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions

April 08, 2021
News

Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure

April 05, 2021
News

The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health

February 24, 2021
News

American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health

February 04, 2021